Mesenchymal stem cells: Stem cell therapy perspectives for type 1 diabetes

Science Direct and Elsevier Masson France


Diabetes & Metabolism 35 (2009) 85–93

L. Vija a,b, D. Farge c, J.-F. Gautier b, P. Vexiau b, C. Dumitrache d, A. Bourgarit c, F. Verrecchia a, J. Larghero e,∗



Mesenchymal stem cells (MSCs) are multipotent non-haematopoietic progenitor cells that are being explored as a promising new treatment for tissue regeneration. Although their immunomodulatory properties are not yet completely understood, their low immunogenic potential together with their effects on immune response make them a promising therapeutic tool for severe refractory autoimmune diseases. Type 1 diabetes is characterized by T cell-mediated autoimmune destruction of pancreatic